Bevacizumab and fotemustine for recurrent glioblastoma: A phase II study of AINO (Italian Association of Neuro-Oncology)

Journal of Neuro-Oncology

Volumn 116, Issue 3, 2014, Pages 533-541

  Soffietti, Riccardo ^a   Trevisan, Elisa ^a   Bertero, Luca ^a   Cassoni, Paola ^a   Morra, Isabella ^a   Fabrini, Maria Grazia ^b   Pasqualetti, Francesco ^b   Lolli, Ivan ^c   Castiglione, Anna ^a   Ciccone, Giovannino ^a   Rudà, Roberta ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Bevacizumab; Fotemustine; Glioblastoma; Nitrosoureas; Recurrence

Indexed keywords

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; ITALY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROLOGIC EXAMINATION; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84894031467     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1317-x     Document Type: Article

References (45)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466. doi: 10.1016/S1470-2045(09)70025-7
3. Grossman SA, Ye X, Piantadosi S et al (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443-2449. doi: 10.1158/1078-0432.CCR-09-3106
4. Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro Oncol 15:4-27. doi: 10.1093/neuonc/nos273
5. Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15:339-347. doi: 10.1002/glia.440150313
6. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740. doi: 10.1200/JCO.2008.19.8721
7. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745. doi: 10.1200/JCO.2008.16.3055
8. Chamberlain MC, Johnston SK (2010) Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96:259-269. doi: 10.1007/s11060-009-9957-6
9. Scoccianti S, Detti B, Sardaro A et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19:613-620. doi: 10.1097/CAD.0b013e3283005075
10. Brandes AA, Tosoni A, Franceschi E et al (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 64:769-775. doi: 10.1007/s00280-009-0926-8
11. Fabrini MG, Silvano G, Lolli I et al (2009) A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92:79-86. doi: 10.1007/s11060-008-9739-6
12. Addeo R, Caraglia M, De Santi MS et al (2011) A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 102:417-424. doi: 10.1007/s11060-010-0329-z
13. Del Vecchio M, Mortarini R, Canova S et al (2010) Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 16:5862-5872. doi: 10.1158/1078-0432.CCR-10-2363
14. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972. doi: 10.1200/JCO.2009.26.3541
15. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259. doi: 10.1158/1078-0432.CCR-06-2309
16. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729. doi: 10.1200/JCO.2007.12.2440
17. Gilbert MR, Wang M, Aldape KD, et al. (2009) RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol. 27(15S) Abstract no 2011
18. Nghiemphu PL, Liu W, Lee Y et al (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217-1222. doi: 10.1212/01.wnl.0000345668.03039.90
19. Francesconi AB, Dupre S, Matos M et al (2010) Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 17:970-974. doi: 10.1016/j.jocn.2009.12.009
20. Hasselbalch B, Lassen U, Hansen S et al (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12:508-516. doi: 10.1093/neuonc/nop063
21. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12:1300-1310. doi: 10.1093/neuonc/noq099
22. Verhoeff JJ, Lavini C, van Linde ME et al (2010) Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 21:1723-1727. doi: 10.1093/annonc/mdp591
23. Desjardins A, Reardon DA, Coan A et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302-1312. doi: 10.1002/cncr.26381
24. Reardon DA, Desjardins A, Peters KB et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107:155-164. doi: 10.1007/s11060-011-0722-2
25. Field KM, Simes J, Wheeler H, et al. (2013) A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). J Clin Oncol 31(15S). Abstract no 2017
26. Raizer JJ, Grimm S, Chamberlain MC et al (2010) A phase 2 trial of single agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297-5305. doi: 10.1002/cncr.25462
27. Taal W, Oosterkamp HM, Walenkamp AME, Beerepoot LV, et al. (2013) A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustinw single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31(15S). Abstract no 2001
28. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9:403-407
29. Metellus P, Coulibaly B, Nanni I et al (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115:4783-4794. doi: 10.1002/cncr.24546
30. Felsberg J, Thon N, Eigenbrod S et al (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659-670. doi: 10.1002/ijc.26083
31. Hammond A, Norden AD, Lesser GJ, et al. (2011) Phase II study of dose-intense temozolomide in recurrent glioblastoma. J Clin Oncol 29(15S) Abstract no 2038
32. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 95:1155-1160. doi: 10.1038/sj.bjc.6603376
33. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361. doi: 10.1200/JCO.2007.10.7722
34. Sadones J, Michotte A, Veld P et al (2009) MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 45:146-153. doi: 10.1016/j.ejca.2008.09.002
35. Kong DS, Lee JI, Kim JH et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12:289-296. doi: 10.1093/neuonc/nop030
36. Stockhammer F, Misch M, Koch A et al (2010) Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100:407-415. doi: 10.1007/s11060-010-0192-y
37. Perry MS, Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051-2057. doi: 10.1200/JCO.2009.26.5520
38. Pope WB, Xia Q, Paton VE et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432-437. doi: 10.1212/WNL.0b013e31820a0a8a
39. Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G et al (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 14:667-673. doi: 10.1093/neuonc/nos070
40. Radbruch A, Lutz K, Wiestler B et al (2012) Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol 14:222-229. doi: 10.1093/neuonc/nor200
41. Wick A, Dörner N, Schäfer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586-592. doi: 10.1002/ana.22336
42. Norden AD, Young GS, Setayesh K (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787. doi: 10.1212/01.wnl.0000304121.57857.38
43. Iwamoto FM, Abrey LE, Beal K (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200-1206. doi: 10.1212/WNL.0b013e3181bc0184
44. Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329-336. doi: 10.1007/s11060-008-9718-y
45. Quant EC, Norden AD, Drappatz J et al (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550-555. doi: 10.1215/15228517-2009-006